Bauer L A, Black D, Gensler A
Department of Pharmacy Practice, SC-69, University of Washington, Seattle 98195.
J Am Geriatr Soc. 1990 Apr;38(4):467-9. doi: 10.1111/j.1532-5415.1990.tb03547.x.
Thirty-six hospitalized male patients receiving oral sustained-release procainamide every six hours for the treatment of ventricular arrhythmias were studied at steady-state before and after oral cimetidine 300 mg every six hours for three days. Average age and weight were 73 +/- 12 (SD) years and 76 +/- 10 kg. Patients did not have a myocardial infarction within the last two years or congestive heart failure and had calculated creatinine clearances (CrCl) between 35 and 75 mL/min/70 kg. Ten patients had urine collections that permitted computation of the ratio between the renal clearance of procainamide and CrCl (PA/CrCl) and the renal clearance of n-acetyl-procainamide (NAPA) and CrCl (NAPA/CrCl). The average steady-state procainamide and NAPA concentrations increased 55% and 36%, respectively, during cimetidine treatment (P less than .01). Twelve patients experienced mild to severe symptoms of what may have been procainamide toxicity. Apparent procainamide oral clearance decreased 41% while patients received cimetidine (P less than .01). PA/CrCl and NAPA/CrCl ratios decreased by 33% and 21%, respectively, during cimetidine therapy (P less than .05). Cimetidine therapy given to older male patients taking procainamide can cause steady-state concentrations of procainamide to rise to toxic levels. Patients prescribed this combination should be monitored carefully for adverse side effects.
对36例因室性心律失常每6小时口服一次普鲁卡因胺缓释剂的住院男性患者进行了研究,在每6小时口服300mg西咪替丁,持续3天前后的稳态期进行观察。患者的平均年龄和体重分别为73±12(标准差)岁和76±10kg。患者在过去两年内无心肌梗死或充血性心力衰竭,计算得出的肌酐清除率(CrCl)在35至75mL/min/70kg之间。10例患者收集了尿液,可计算出普鲁卡因胺肾清除率与CrCl的比值(PA/CrCl)以及N-乙酰普鲁卡因胺(NAPA)肾清除率与CrCl的比值(NAPA/CrCl)。在西咪替丁治疗期间,普鲁卡因胺和NAPA的平均稳态浓度分别增加了55%和36%(P<0.01)。12例患者出现了可能是普鲁卡因胺毒性的轻至重度症状。在患者接受西咪替丁治疗时,普鲁卡因胺的表观口服清除率降低了41%(P<0.01)。在西咪替丁治疗期间,PA/CrCl和NAPA/CrCl比值分别下降了33%和21%(P<0.05)。对服用普鲁卡因胺的老年男性患者给予西咪替丁治疗可导致普鲁卡因胺的稳态浓度升高至中毒水平。开具此联合用药的患者应密切监测不良反应。